Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01766817 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
A Phase 2 study of Idiopathic Pulmonary Fibrosis, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 2
- Development phase
- 325
- Enrollment target
- 20
- Study locations
NCT01766817 is a Phase 2 study of Idiopathic Pulmonary Fibrosis that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 325 participants, below the 745-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (56% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT01766817, a Phase 2 study of Idiopathic Pulmonary Fibrosis, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 325 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).
Conditions Studied
Interventions
- DRUG BMS-986020
- DRUG Placebo matching with BMS-986020
Study Locations (20)
California
- Cedars-Sinai Medical Center - Los Angeles
- David Geffen School of Medicine at UCLA - Los Angeles
- University of California at San Francisco - San Francisco
- Stanford University Medical Center - Stanford
Florida
- Advanced Pulmonary & Sleep Research Institute of Florida - Daytona Beach
- University of Florida - Gainesville
- ILD Research Center - Miami
- Cleveland Clinic Florida- Weston Hospital - Weston
Kentucky
- University of Kentucky- Center for Clinical and Translational Science - Lexington
- University of Louisville - Louisville
Massachusetts
- Brigham and Women's Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
Alabama
- University of Alabama at Birmingham - Division of Pulmonary, Allergy & Criticial Care - Birmingham
Arizona
- St. Joseph's Hospital and Medical Center - Heart Lung Institute/ Clinical Research - Phoenix
Colorado
- National Jewish Health - Denver
Connecticut
- Yale University School of Medicine, Section of Pulmonary & Critical Care - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2013-01-31 |
| Est. Completion | 2016-02-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01766817
The ClinicalTrials.gov registry entry for NCT01766817 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 325 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 745-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (56% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 2 interventions - of which BMS-986020 is the first listed.
NCT01766817 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Kentucky.
Frequently Asked Questions
What is clinical trial NCT01766817 about?
NCT01766817 is a clinical study titled "Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis". The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).
What is the current status of trial NCT01766817?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 325 participants. The study started on 2013-01-31. Estimated completion is 2016-02-29.
What conditions does trial NCT01766817 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT01766817?
The interventions under investigation include: BMS-986020 (DRUG), Placebo matching with BMS-986020 (DRUG).
Who is sponsoring clinical trial NCT01766817?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01766817 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 2
-
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
RECRUITING · Phase 2
-
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
RECRUITING · Phase 2
-
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
RECRUITING · Phase 2
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.